leisure time -WSS

leisure time

author：hotspot 2025-08-12 06:42:19 - browse：33

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： STAT Wunderkinds: Ruey Hu's digital tools for parsing research

focus

WSS

Readout Newsletter: What happened with Sarepta's Duchenne data

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Emergency medicine has repudiated 'excited delirium.' Now what?

Senators: Long

Readout Newsletter: XBI biotech index, Akero Therapeutics

Diversifying clinical trials isn't enough to close racial gaps: study

hotspot

leisure time

entertainment

The high cost of giving birth even with insurance

CDC recommends rationing of RSV shot due to shortages

ChatGPT in medicine: STAT answers readers' burning questions

Lasker Awards 2023: Winners in biomedical research

Duchenne breakthrough therapy leaves behind pioneering families

Senate panel to vote on hospitals, PBMs, prisoner care

Moonlake's readout produced a cash windfall. Risks remain

STAT Virtual Event: Putting AI to the Test

The cancer drug shortage isn’t new — and neither are the solutions

Chimpanzees, like humans and whales, get menopause: Study

leisure time

Senate panel to vote on hospitals, PBMs, prisoner care

EpiPen alternative approval delay highlights citizen petition issue

Readout Newsletter: What happened with Sarepta's Duchenne data

Second xenotransplant done with gene

Readout Newsletter: XBI biotech index, Akero Therapeutics

Hearing on Medicare drug price negotiation gets unusually heated

entertainment

focus

focus

hotspot